Category Archives: Public Policy

Latest From Public Policy

A National Blueprint for Biodefense Released Today

ebola

A major report was released today detailing findings and recommendations to improve the U.S. biodefense readiness. “A National Blueprint for Biodefense: Leadership and Major Reform Needed to Optimize Efforts” was authored by the Blue Ribbon Study Panel on Biodefense, on which BIO President and CEO Jim Greenwood serves. The panel is co-chaired by former Sen. Joe Lieberman and former Gov. Tom Ridge. Other panelists include former Secretary of Health and Human Services Donna Shalala, former Read More >

Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: ,

Biotech Policy Outlook at #BIF15: 21st Century Cures, IPR, TPP, and PDUFA VI

To even the most casual observer, 2015 has been a big year in the biotech industry, particularly in Congress and in other venues wherein public policies that affect the sector take shape. Given the importance of the policy environment in determining how successful companies in our industry can be at delivering new cures and treatments to patients – and a return to the investors who finance their activities – we decided that a close look Read More >

Events, Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

PTAB Ruling Proves Medical Innovation Under Attack

US_Patent_And_Trademark_Office

There’s more evidence today that the IPR system needs to be fixed. PTAB ruled on Friday that under current rules, hedge fund managers are free to manipulate the system by shorting drug company stocks and then challenging their patents. Here’s what the panel said: “Profit is at the heart of nearly every patent and nearly every inter partes review. As such, an economic motive for challenging a patent claim does not itself raise abuse of Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , ,

BIO on CNBC: IPR System Weakens Medical Innovation

ron-cohen_115x76

Last night Ron Cohen, M.D., CEO of Acorda Therapeutics and BIO’s board chair, appeared on CNBC’s Fast Money where he discussed our industries concerns’ with the U.S. Patent and Trademark Office’s patent challenge system known as Inter Partes Review (IPR). Dr. Cohen concisely explained this complicated and rapidly evolving issue and made clear why Congress must quickly address abuses to the IPR system within current Patent reform legislation. Regrettably, this system that was designed by Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Here are the Facts about the IPR Kill Rate

US_Patent_And_Trademark_Office

FiercePhrma recently ran an article repeating a dubious analysis of the crisis caused by the rapidly increasing number of biopharma related inter partes reviews (IPR) currently within the United States Patent and Trademark Office (PTO). It is troubling that in a single breath Ronny Gal both dismissed the biopharmaceutical industry’s concerns with the PTO’s IPR process and acknowledged that limited data prevents any firm conclusions about the potential impact of IPR on biotech innovation. If Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , ,